Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Lonza : to Host New Webinar 'Paper to EBR in 9 Months How a Strong Collaboration Leads to Project Success'

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/29/2019 | 04:54am EST

Basel - On 12 November, Lonza will host a free 60-minute webinar during which Nephron Pharmaceuticals will explain its decision to take a paperless approach to batch record management.

Nephron will also discuss how its close relationship with Lonza allowed for a rapid implementation of Lonza's MODA-ESTM Electronic Batch Record (EBR) Platform in just nine months, leading to increased operational efficiency and expanded product lines.

Recording batch data is an essential part of the pharmaceutical manufacturing process. However, the wealth of information generated by each batch is traditionally collected using paper-based workflows, which are inherently resource intensive, time consuming and can negatively impact the time-to-market for new therapeutics. As such, pharmaceutical manufacturers are increasingly turning to paperless EBR solutions to eliminate these challenges.

In the webinar titled 'Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success,' Bryan Beck, Vice President for Automation and Information Technology at Nephron Pharmaceuticals, will discuss the following topics

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.

Contact:

Dr. Kristin Koehler

Tel: +41 61 316 8782

Email: kristin.koehler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
11/27Pfizer, Novartis lead $2 billion spending spree on gene therapy production
RE
11/21LONZA : Navrogen Inc. and Lonza Sign Agreement to Use Lonza's GS Gene Expression..
AQ
11/14LONZA : New eCHO Basal Medium and Feed Facilitates Late-Stage Cell Viability and..
AQ
11/12Board Announcement
TE
11/06CRYOPORT : Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Deliv..
AQ
10/29LONZA : to Host New Webinar 'Paper to EBR in 9 Months How a Strong Collaboration..
AQ
10/23LONZA : Announces Short, Routine Shutdown of Niacinamide Plant in Nansha for Mai..
AQ
10/18MESOBLAST : and Lonza Enter GVHD Commercial Manufacturing Agreement
AQ
10/17LONZA : Strengthens Sports Nutrition Portfolio with the Launch of Vegan MuscleGu..
AQ
10/17MESOBLAST : and Lonza Enter into Agreement for Commercial Manufacture of Mesobla..
AQ
More news
Financials (CHF)
Sales 2019 5 905 M
EBIT 2019 1 204 M
Net income 2019 723 M
Debt 2019 3 215 M
Yield 2019 0,84%
P/E ratio 2019 34,8x
P/E ratio 2020 29,3x
EV / Sales2019 4,83x
EV / Sales2020 4,47x
Capitalization 25 281 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 374,86  CHF
Last Close Price 340,50  CHF
Spread / Highest target 35,7%
Spread / Average Target 10,1%
Spread / Lowest Target -19,2%
EPS Revisions
Managers
NameTitle
Marc Funk Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP33.69%25 505
IQVIA HOLDINGS INC.27.82%28 813
INCYTE CORPORATION48.58%20 351
SEATTLE GENETICS, INC.107.38%20 138
CELLTRION, INC.--.--%18 265
ALNYLAM PHARMACEUTICALS, INC.69.74%13 798